Filipinas - inglés - FDA (Food And Drug Administration)

medethix, inc.; distributor: multicare pharmaceuticals phils. inc. - salmeterol (as xinafoate) , fluticasone propionate - metered dose inhaler - 25 mcg/125 mcg

Filipinas - inglés - FDA (Food And Drug Administration)

medethix, inc.; distributor: multicare pharmaceuticals phils. inc. - salmeterol (as xinafoate) , fluticasone propionate - metered dose inhaler - 25mcg/250 mcg

Filipinas - inglés - FDA (Food And Drug Administration)

medethix, inc.; distributor: multicare pharmaceuticals phils. inc. - salmeterol (as xinafoate) , fluticasone propionate - metered dose inhaler - 25mcg/50 mcg

Filipinas - inglés - FDA (Food And Drug Administration)

biocare lifesciences inc.; distributor: multicare pharmaceuticals phils. inc. - salmeterol (as xinafoate) , fluticasone propionate - metered dose inhaler - 25mcg/125mcg per actuation

Filipinas - inglés - FDA (Food And Drug Administration)

biocare lifesciences inc.; distributor: multicare pharmaceuticals phils. inc. - salmeterol (as xinafoate) , fluticasone propionate - metered dose inhaler - 25mcg/250mcg

Filipinas - inglés - FDA (Food And Drug Administration)

innogen pharmaceuticals, inc.; importer: n/a; distributor: multicare pharmaceuticals phils. inc. - salmeterol (as xinafoate) , fluticasone propionate - dry powder for inhalation in capsule - 50 mcg/250 mcg

Filipinas - inglés - FDA (Food And Drug Administration)

innogen pharmaceuticals, inc; importer: n/a; distributor: multicare pharmaceuticals phils. inc. - salmeterol (as xinafoate) , fluticasone propionate - dry powder for inhalation in capsule - 50 mcg/500 mcg

Australia - inglés - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. evocair is not indicated for the initiation of bronchodilator therapy in copd.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluticasone propionate, quantity: 125 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. evocair is not indicated for the initiation of bronchodilator therapy in copd.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.